Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORPIO
  • Sponsors Astellas Pharma; Astellas Pharma Europe Ltd

    • Most Recent Events

    • 15 Apr 2014 Pooled results for urinary retention rates presented at the 29th Congress of the European Association of Urology.
    • 08 May 2013 Tolerability results from a pooled analysis presented at the 108th Annual Meeting of the American Urological Association.
    • 08 May 2013 Pooled efficacy analysis presented at the 108th Annual Meeting of the American Urological Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top